IP Library Granted Patent US 9,844,589
Granted Patent B2
US 9,844,589 · App. 13/137,517 · Granted Dec 19, 2017

Modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins capable of inducing broadly reactive T- and B-cell responses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,844,589
App. No.
13/137,517
Granted
Dec 19, 2017
Kind
B2
Abstract

The invention relates to HIV-1 envelope polypeptides comprising the consensus envelope of SEQ ID NO: 35, compositions comprising these envelopes and methods for using same.

Claims (11)

1. A recombinant protein comprising the sequence of amino acids set forth in FIG. 29A (SEQ ID NO: 35).

2. A composition comprising the recombinant protein according to claim 1 and a carrier.

3. The recombinant protein according to claim 1 , wherein the sequence of said protein consists of SEQ ID NO: 35.

4. The composition of claim 2 , wherein the protein consists of SEQ ID NO: 35.

5. The composition of claim 2 or 4 further comprising an adjuvant.

6. A method of inducing an immune response in a mammal comprising administering to said mammal the composition of claim 2 , 4 or 5 in an amount sufficient to effect such induction.

7. A recombinant gp120 envelope protein derived from SEQ ID NO: 35, wherein the recombinant gp120 envelope protein comprises the consecutive amino acid sequence represented by amino acid numbers 30 to 484 of SEQ ID NO: 35.

8. The recombinant gp120 envelope protein of claim 7 , wherein the recombinant gp120 envelope protein consists of the consecutive amino acid sequence represented by amino acid numbers 30 to 484 of SEQ ID NO: 35.

9. A composition comprising the recombinant protein according to claim 7 or claim 8 and a carrier.

10. The composition of claim 9 further comprising an adjuvant.

11. A method of inducing an immune response in a mammal comprising administering to said mammal the composition of claim 9 or 10 in an amount sufficient to effect such induction.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2018
From: LOS ALAMOS NATIONAL SECURITY, LLC
To: TRIAD NATIONAL SECURITY, LLC
Reel/Frame 047485/0173 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2016
From: KORBER, BETTE T.
To: LOS ALAMOS NATIONAL SECURITY, LLC
Reel/Frame 037739/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2016
From: HAHN, BEATRICE H; SHAW, GEORGE M; KOTHE, DENISE; LI, YING YING; DECKER, JULIE
To: THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION
Reel/Frame 037836/0855 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2016
From: HAYNES, BARTON F; GAO, FENG; LIAO, HUA-XIN
To: DUKE UNIVERSITY
Reel/Frame 037837/0034 →
CONFIRMATORY LICENSE Recorded Feb 19, 2013
From: LOS ALAMOS NATIONAL SECURITY
To: U.S. DEPARTMENT OF ENERGY
Reel/Frame 029835/0699 →